Gary, it is indeed still the protocol that was use

Gary, it is indeed still the protocol that was used in the trial in Israel.

I have no idea why you keep harping about the same issue and the need for the company to publicly update this site. I first contacted management about this very issue back on March 9, 2017. After numerous follow-up emails I got a reply from Alon Sinai addressing my concerns. I shared the email response not only with you but with many others on this board. Mr. Sinai made it very clear why they do business the way they do. You don't have to like it, but you are not part of management. By all means contact the company and offer your services. But to continue playing the same tune on this board for well over a year now is getting tiresome.

For those of you that are new or have forgotten here is the reply I received from Alon Sinai:

Sent: Thursday, May 11, 2017 2:39 PM
Subject: RE: NCT02976779, OWC-PSO-01, A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers

Dear Frank and Hello everyone,

First , thank you for contacting us .

I will try and stay as short and to the point as possible.

General:

OWC pharmaceutical research is a biotech company and not a toy manufacturer in an automated China production line .

I am sure you realize that R&D and exploring new inventions is unknown road . It's a road we have to build .

Luckily for you as a shareholder and us as a company our pre-clinical phase for the cream's efficacy study led to findings that ( being very careful) are unique , with no previous records of any scientific findings , even remotely close to what we found ! Up to 70% reduction of biological markers directly related to psoriasis.

FYI , pre-clinical = on human tissues but not on human beings .

I am also aware of many "web-speculations" on timing and scientific course . None of them is supported by any of the official company's filings or communications!

Last , as a prolog to my answers to your inquiry let me add :

I am not sure if you are aware at what conducting a safety clinical study ( similar to FDA phase I) so let me give you some highlights :

1. The tested people have to be 100% healthy and none biased .

2. They have to be picked Randomly ( responding to Adds) and prove that they are not associated with the company or its competitors.

3. After the first screening they have to go through physical and mental check up ( for instance , once we checked some of the volunteers we happily advised 2 women that they are pregnant)

4. Than all volunteers are invited to the hospital to try and determine , for each of them , dates and timing for attending the hospital. During the study some are always asking to re-schedule , due to personal issues .

There are many other items and pieces that has to fall in place to finish building the puzzle . That is why with most studies the safety stage is framed to take a year


your inquiries below :

1. NIH reporting system is not a "FedEx" tracking system . Most biotech companies report only final results , some report midterm. All for purpose of protecting IP and disclose as less as possible to their competitors. So do we

2. You cannot chose to volunteer from the follow reasons :

* all volunteers were chosen already

* in order to volunteer at the beginning, you had to reside in Israel and able to arrive at the hospital, twice a week for 3 months

Last

Our main focus right now Is :

* complete including our pre-clinical findings into our IP so it will be stronger and un breakable. ( we announced)

* follow up to the vested interest we generated with international organizations ( commercial and scientific) after we announced the pre clinical findings

* continue the preparations to get our product to the market

So forgive me , in advance , if I don't answer fast enough

Thanks

Alon

Alon Sinai, COO

One World Cannabis Ltd. (OWC)

22, Shacham Street (Beit Dvir, 2nd floor), Petach Tikva, Israel

Mailing Address: PO Box 8324, Petach Tikva, 4918103, Israel

Tel: + 972 (0)3 7582659; + 972 (0)52 4029178

Email: alon.sinai@OWCpharma.com

www.OWCpharma.com